A Single-arm, Multi-centre Trial to Evaluate Efficacy and Safety of Imlifidase in Highly Sensitised Children (1-17 Years) Receiving a Kidney Transplant With Positive Crossmatch Against a Living or Deceased Donor Converted to Negative After Imlifidase Treatment
Latest Information Update: 10 Feb 2025
At a glance
- Drugs Imlifidase (Primary)
- Indications Kidney-pancreas transplant rejection
- Focus Pharmacodynamics
- Acronyms DINKY
- Sponsors Hansa Biopharma AB
- 04 Feb 2025 Planned End Date changed from 30 Sep 2029 to 31 Aug 2031.
- 04 Feb 2025 Planned primary completion date changed from 30 Sep 2024 to 28 Feb 2027.
- 22 May 2024 According to a Hansa Biopharma media release results will be presented at the American Transplant Congress (ATC), the joint annual meeting of the American Society of Transplant Surgeons (ASTS) and the American Society of Transplantation (ATS).